linjc16/ctgov huggingface dataset:
Detecting Lesions in the Oral Cavity With Thermal Imaging

Study Overview
=================
Brief Summary
-----------------
Previous studies indicate that there are significant differences in the temperature of tumors and normal, adjacent tissues. The present study will test this hypothesis for lesions in the oral cavity. Thermal images of the oral cavities of patients, undergoing examination in the Department of Oral and Maxillofacial Surgery of Sheba hospital, will be compared to the diagnoses of the examining doctors. The results, apart from enhancing the delineation of oral cavity tumors, may help the decision to develop miniature thermal cameras to scan thermally, the GI tract.

Official Title
-----------------
Detecting Lesions in the Oral Cavity With Thermal Imaging

Conditions
-----------------
Carcinoma, Squamous Cell

Intervention / Treatment
-----------------
* Other: no intervention, observation only


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed in the Department of Oral and Maxillofacial Surgery as suffering from malignant or possibly malignant lesions. Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| possible oral cancer<br>Patients reporting for oral cavity examination with the possibility or certainty of oral lesions | Other: no intervention, observation only<br>* Oral cavity will be imaged by a thermal camera.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ability of a thermal camera to detect and delineate tumors in the oral cavity |  | during and immediately after the examination | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
oral cavity, carcinoma, thermal imaging
Goals of Sexual Function in Prostate Cancer Survivors and Their Partners After Cancer Treatment

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Gathering information about survivors of prostate cancer and their partners may help doctors learn more about the goals for sexual functioning after cancer treatment. PURPOSE: This clinical trial is studying the goals of sexual functioning in prostate cancer survivors and their partners after cancer treatment.

Detailed Description
-----------------
Detailed DescriptionOBJECTIVES: I. To collect data on the goals of sexual functioning among prostate cancer survivors and their partners following cancer treatment in order to identify specific components of interventions for future grant submissions on the psychosexual needs of prostate cancer survivors. OUTLINE: Patients and their partners complete surveys. Sexual function of men is assessed by the International Index of Erectile Function; sexual function of women is assessed by the Female Sexual Function Index.

Official Title
-----------------
Goals for Sexual Functioning of Prostate Cancer Survivors and Their Partners Following Cancer Treatment

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Other: Survey Administration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Prostate cancer survivors who are: willing and able to provide informed consent; able to read, write, and speak English; married or are in married-like relationship; completed radiation or surgery for their prostate cancer 6 months to 5 years ago Partners of prostate cancer survivors must be: willing and able to provide informed consent; able to read, write, and speak English Exclusion Criteria: Prostate cancer survivors will be excluded if they have undergone androgen deprivation therapy within the past 6 months and if their partners refuse to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm I<br>Patients and their partners complete surveys. Sexual function of men is assessed by the International Index of Erectile Function; sexual function of women is assessed by the Female Sexual Function Index. | Other: Survey Administration<br>* Patients complete survey<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Goals of sexual functioning |  | 2 years |
COVID-19 Among Egyptian Health Care Providers

Study Overview
=================
Brief Summary
-----------------
The study aims to identify COVID 19 knowledge, working conditions, perception of anxiety and stigma among Egyptian health care providers as well as their predictors.

Official Title
-----------------
Knowledge, Attitude, Perceived Worry and Stigma About COVID-19 Among Egyptian Health Care Providers

Conditions
-----------------
COVID

Intervention / Treatment
-----------------
* Other: self-administered questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Health care providers include physicians, nurses, and health officers both medical and nursing subjects. Exclusion Criteria: Medical students
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| study group<br>Health care providers include physicians, nurses, and health officers both medical and nursing subjects. | Other: self-administered questionnaire<br>* Data will be collected using Google online self-administered questionnaire disseminated in Arabic language<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percentage of knowledge regarding COVID-19 information |  | 10 minutes |
Influence of an Endometrioma on Oocyte Quality

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate if there are differences in oocyte quality depending on whether these oocytes come from an ovary in contact with an endometrioma.

Detailed Description
-----------------
There is no consensus for whether an endometrioma influences oocyte quality, as well as the possible mechanisms that induce them. In this study, the oocyte maturation will proof oocyte quality: This mean, the percentage of oocytes in metaphase II obtained after stimulation, as well as the rate of oocytes fertilized in direct contact with an endometrioma.

Official Title
-----------------
Influence of an Endometrioma on Oocyte Quality

Conditions
-----------------
Endometriosis

Intervention / Treatment
-----------------
* Other: Collect retrospectively data


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients <40 years, BMI <30kg / m2, Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Endometriosis<br>No drugs are administered. It is an observational study. Collect retrospectively data | Other: Collect retrospectively data<br>* Collect retrospectively data<br>|
| No endometriosis<br>No drugs are administered. It is an observational study. Collect retrospectively data | Other: Collect retrospectively data<br>* Collect retrospectively data<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of mature oocytes | Number of MII oocytes from the total of cumulus granulosa cell-oocyte complex by 100 | Up to 36 months | 
| Fertilization rate | Number of oocytes with pronuclear activation after ICSI procedure from the total oocytes microinjected by 100 | Up to 36 months |
Multifactorial Evaluation of COVID-19 Respiratory Reliquates

Study Overview
=================
Brief Summary
-----------------
The present study aims to evaluate how commonly diagnostic tools employed in the preoperative evaluation of respiratory function in thoracic surgery can identify pathological alteration due to a previous SARS-CoV-2 infection. In particular, the investigators will gather information concerning imaging (lung ct and lung ultrasound), arterial blood gas analysis, and pulmonary function tests.

Official Title
-----------------
Multifactorial Evaluation of COVID-19 Respiratory Reliquates

Conditions
-----------------
COVID-19 Respiratory Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: previous SARS-Cov2 infection awaiting lung resection surgery Exclusion Criteria: less than 18 years of age unable to consent to enroll refuse to enroll

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID-19 previous infection<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sensibility of preoperative evaluation in identifying pathological sequelae due to SARS-Cov2 infection |  | 12 month |
Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children

Study Overview
=================
Brief Summary
-----------------
To compare the ability of Prevnar® to Pneumo® 23 in reducing and preventing nasopharyngeal carriage of vaccine-type pneumococci one year after respective immunization. To evaluate the rate of penicillin-resistant pneumococci in nasopharyngeal carriage.

Detailed Description
-----------------
This study will require 6 months to be completed (3 months for nasopharyngeal samples collection; 3 months dor analysis). Each child will participate for a 1 day period.

Official Title
-----------------
Long-Term Efficacy of Pneumococcal Conjugate 7-Valent Vaccine Versus Plain Polisaccharide Pneumococcus Vacine in Reducing Pneumococcal Nasopharyngeal Carriage of Children.

Conditions
-----------------
Vaccines, Pneumococcal, Vaccines, Pneumococcal Conjugate Vaccine

Intervention / Treatment
-----------------
* Biological: pneumococcus conjugate vaccine 7 valent to reduce carriage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy children between 2 to 9 years old. No history of antibiotic use prior 1 month of enrollment No history of invasive pneumococcal disease

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: G1<br>G1: prevenar | Biological: pneumococcus conjugate vaccine 7 valent to reduce carriage<br>* plain polisacaride vaccine 23 valent to reduce carriage<br>|
| Active Comparator: G2<br>G2: pneumo 23 | Biological: pneumococcus conjugate vaccine 7 valent to reduce carriage<br>* plain polisacaride vaccine 23 valent to reduce carriage<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the ability of Prevnar® to Pneumo® 23 in reducing and preventing nasopharyngeal carriage of vaccine-type pneumococci one year after respective immunization. |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the rate of penicillin-resistant pneumococci in nasopharyngeal carriage. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pneumococcus conjugated vaccine 7 valent
Observation and Progressive Strength Training After Hip Fracture

Study Overview
=================
Brief Summary
-----------------
This is a randomized, controlled; single-blind parallel group trial carried out with hip fracture patients, starting at 12 weeks post fracture. Patients were approached during their acute stay in hospital, followed without any extra intervention for 12 weeks, and then randomized in a 2:1 manner to either intervention or control for the next 12 weeks. After the first 12 weeks intervention the intervention group were divided into two groups and randomized to an new single-blind parallel group trial for further intervention.

Official Title
-----------------
Observation and Progressive Strength Training After Hip Fracture

Conditions
-----------------
Exercise

Intervention / Treatment
-----------------
* Other: Strength training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:at 12 weeks postoperative: age at least 65 years not living in nursing home were able to undergo physical therapy for the hip fracture scoring of 23 or more (out of 30) on the Mini Mental State Examination Exclusion Criteria: permanently institutionalized had metastatic cancer suffered from multi-trauma.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Usual care<br>Subjects in the control group were asked to maintain their current lifestyle. No restrictions were placed on their exercise activities. | Other: Strength training<br>* Strength training for 24 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bergs Balance scale | Bergs Balance Scale: The Berg balance scale (BBS) measures functional balance, which has three dimensions: maintenance of a position, postural adjustment to voluntary movements, and reaction to external disturbance, scored 0-56 (Berg K. 1995). | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Strength | Secondary outcomes was the results on the Sit to Stand-test,which measure strength of lower limbs. | 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Strength, Function, Mobility
TRIM: Danish Form and Dose Study on Vitamin B12

Study Overview
=================
Brief Summary
-----------------
The study investigates the absorption of different doses of hydroxocobalamin and cyanocobalamin in a vitamin B12-replete Danish population.

Official Title
-----------------
TRIM: Danish Form and Dose Study in Vitamin B12

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: Vitamin B12


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years old Exclusion Criteria: Use of vitamin pills with vitamin B12 within the last two weeks of the study Treatment with vitamin B12 injections within the last year Known chronic systemic disease Not able to give informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: cyano-hydroxo B12<br>Absorption of 3 doses of 9 ug cyano-B12 and 9 ug hydroxo-B12 for two days (the CobaSorb test). No drugs given. | Dietary Supplement: Vitamin B12<br> <br> * Other names: Cobalamin;|
| Active Comparator: Cyano-B12 doses<br>Absorption of 3 doses of 3 ug, 6 ug, and 9 ug cyano-B12 for two days (the CobaSorb test). No drugs given. | Dietary Supplement: Vitamin B12<br> <br> * Other names: Cobalamin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vitamin B12 absorption (increase in holotranscobalamin) |  | 3 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
absorption of Vitamin B12
Comparison of Tension Free Primary Closure, Karydaks and Limberg Flap Methods

Study Overview
=================
Brief Summary
-----------------
Pilonidal sinus is a chronic inflammatory disorder of intergluteal sulcus. The disease seen in between 15-35 years of age and 3-4 times more in males. The incidence of the disease is found as 8.8% in Turkish soldiers. The disorder mainly affects the quality of life. There are numerous methods in surgical treatment of Pilonidal sinus. The main difference in between those methods is the closing of the defect that occurs after the excision of the sinus tract. The defect can be closed by primary sutures or it can be left for secondary healing. Nowadays, the recurrence rate of flap procedures are lower therefore, flap procedures are commonly used. However, it has been reported that there is no difference between flap procedures and tension free primary closure. This result triggered the controversy that; if the healing side is tension free, midline suturing may have no importance. The aim of this study is to compare the results of 3 different surgical procedures used in treatment of pilonidal disease.

Official Title
-----------------
Randomised Prospective Comparison of Tension-free Primary Closure, Karydakis and Limberg Flap Methods in Treatment of Pilonidal Sinus Disease

Conditions
-----------------
Pilonidal Disease, Recurrence, Complication

Intervention / Treatment
-----------------
* Procedure: tension free primary closure
* Procedure: karydakis
* Procedure: Limberg flap


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: having pilonidal sinus disease desire for surgical treatment accept to be involved in the study Exclusion Criteria: patients under age of 18 recurrent cases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: tension free primary closure<br>patients treated by tension free primary closure | Procedure: tension free primary closure<br>* tension free primary closure of the defects created by excision of the pilonidal sinus<br>|
| Experimental: karydakis<br>patients treated by Karydakis method | Procedure: karydakis<br>* the defect after excision of the pilonidal sinus is closed by Karydakis procedure<br>|
| Experimental: Limberg flap<br>patients treated by Limberg flap procedure | Procedure: Limberg flap<br>* defect after excision of the pilonidal sinus is closed by Limberg flap procedure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recurrence | recurrence rates two years after the surgery | 2 years |
Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effectiveness and safety of Olostar Tab in patients with essential hypertension and dyslipidemia

Official Title
-----------------
A Non-interventional, Multi-center, Retrospective Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia (ROSE Study)

Conditions
-----------------
Hypertension, Dyslipidemias

Intervention / Treatment
-----------------
* Drug: Other: Not applicable-observational study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female ≥ 19 Patients have record of blood pressure (SBP/DBP) and LDL-C after prescription of Olostar Tab. Exclusion Criteria: Patients that have participated clinical trials or PMS with Olostar Tab.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Other: Not applicable-observational study|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent change from baseline in blood pressure (SBP/DBP) |  | At 8 Weeks | 
| Percent change from baseline in LDL-Cholesterol (LDL-C) |  | At 8 Weeks |